论文部分内容阅读
生长抑素和性激素释放素(黄体化激素-释放激素,LH-RH)对胰腺腺癌具有显著的抑制作用,这已为实验研究所证明。根据流行病学调查发现,胰腺癌病人,男性多于女性,实验证明,人类胰腺癌细胞具有性激素受体,生长抑素和LH-RH均有抑制胰腺癌的作用,尤其在两种联用时抑制作用更为明显。本文以前瞻性临床研究比较了这两种药单独使用和联合使用时,对不能施行根治性切除的胰腺腺癌的治疗效果。
Somatostatin and sex hormone-releasing hormone (Luteinizing hormone-releasing hormone, LH-RH) has a significant inhibitory effect on pancreatic adenocarcinoma, which has been proved by the experimental research institute. According to epidemiological investigations, pancreatic cancer patients are more often men than women. Experiments have shown that human pancreatic cancer cells have sex hormone receptors, and somatostatin and LH-RH all inhibit pancreatic cancer, especially in the two combinations. The effect is even more pronounced. This prospective clinical study compared the therapeutic efficacy of these two drugs when used alone and in combination to treat pancreatic adenocarcinoma that cannot undergo radical resection.